Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors

计划入组 45 人 · 首次发布于 2017 年 6 月 5 日

Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

计划入组 46 人 · 首次发布于 2004 年 12 月 8 日

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

计划入组 1,150 人 · 首次发布于 2007 年 6 月 27 日

RAF-709

RAF-265

C₂₄H₁₆F₆N₆O

Raf-1 LE-siRNA

Exelixis, Inc.

United States

Inhibikase Therapeutics

United States

Regeneron Pharmaceuticals

United States

Major Kinase Inhibitor Summit to Showcase Next-Generation Cancer Therapeutics Advances

Day One Biopharmaceuticals Advances FIREFLY-2 Trial and Reports Progress in DAY301 Study

Oncology Drug Development Pipeline Remains Robust, Driven by Novel Therapies and Cell Therapies